Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapix Biosciences Ltd ADR TRPXY

Healthcare Biotechnology
Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

Recent & Breaking News (OTCPK:TRPXY)

SciSparc Engages Procaps for Development and Production of CannAmide(TM) and its SCI-110 Product Candidate

PR Newswire February 10, 2021

SciSparc Initiates Commercial Production of its CannAmide(TM) Pills

PR Newswire February 9, 2021

Therapix Biosciences Announces Name Change to SciSparc Ltd.

PR Newswire January 28, 2021

Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada

PR Newswire January 5, 2021

Therapix Biosciences Announces Upgrade to OTCQB Venture Market

PR Newswire December 8, 2020

Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain

PR Newswire December 2, 2020

Therapix Biosciences Issues CEO Letter to its Shareholders

PR Newswire November 30, 2020

Therapix Biosciences Announces Pricing of $4.2 Million Offering

PR Newswire November 19, 2020

Therapix Biosciences Announces Replacement of its Board of Directors

PR Newswire August 21, 2020

Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court

PR Newswire July 9, 2020

Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court

PR Newswire July 1, 2020

Therapix Biosciences Raises $2.6 Million in Private Placement

PR Newswire June 29, 2020

Pure Capital Demands Replacement of Therapix Biosciences Ltd.'s Board of Directors

GlobeNewswire June 2, 2020

Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication

PR Newswire May 19, 2020

Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors

PR Newswire May 7, 2020

Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements

PR Newswire April 28, 2020

Therapix Biosciences Announces Appointment of New CEO

PR Newswire April 22, 2020

Therapix Biosciences Announces Pricing of $1.25 Million Public Offering

PR Newswire April 1, 2020

Therapix Biosciences Ltd. Announces Shareholder Conference Call

PR Newswire March 25, 2020

Therapix Biosciences Ltd. Signs Securities Purchase Agreement

PR Newswire March 19, 2020